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Oncolo
3-5013Abstract—Ultrasonography is a non-invasive, accurate and low-cost technique used to study the upper abdomen,
but it has reduced reliability in the study of the pancreas and retroperitoneum. Simethicone is a well-known emul-
sifying agent that has been used to improve ultrasonographic visualization. The aim of this study was to identify
anthropometric parameters that are able to predict a good response to simethicone in improving ultrasonographic
visualization of abdominal structures. One hundred twenty-seven patients were recruited. After basal examina-
tion, their anthropometric parameters were collected. Patients with an incomplete upper abdominal examination
because of gastrointestinal gas have greater body mass index, waist circumference and abdominal wall thickness.
In our study, the best anthropometric parameter for identifying patients with poor visualization at abdominal ul-
trasound examination is waist circumference. Using a cutoff of 84 cm, we can identify patients with poor visibility
at abdominal ultrasound examination (group B) with a sensitivity of 90%. (E-mail: tom.gabbani@gmail.
com)  2016 World Federation for Ultrasound in Medicine & Biology.
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Ultrasonography (US) is a non-invasive, accurate and
low-cost technique used to study the upper part of the
abdomen, but it has a reduced reliability in the study of
pancreas and retroperitoneum (Ishigami et al. 2014;
Warren et al. 1978). The limitation during exploration
of the pancreas is often attributed to meteorism caused
by excess gas in the stomach or gut in majority of the
cases. Several techniques have been used to improve
pancreatic US imaging, but these techniques have had
limited success (Rosenberg et al. 1982). If the visualiza-
tion of the pancreas or other abdominal structures is poor,
frequent computed tomography (CT) scan or a magnetic
resonance imaging (MRI) should be performed although
at a high health care cost. In recent years, many different
pre-medications have been proposed to improve ultra-
sound imaging quality of the upper abdomen with good
results. Authors have proposed the use of oral cellulose-
based contrast medium (Harisinghani et al. 1997). Othersddress correspondence to: Tommaso Gabbani, Dipartimento
gico Gastroenterologia SOD 1, AOU Careggi, Largo Brambilla,
9 Firenze, Italy. E-mail: tom.gabbani@gmail.com
2532have suggested the administration of water (Lev-Toaff
et al. 1999). Moreover, some authors have even proposed
the use of enemas, provoking considerable discomfort for
the patient without obtaining satisfactory results (Friis
et al. 1991; Weighall et al. 1979). Several studies have
reported improved visualization of abdominal
structures, particularly the pancreas, using oral specific
pre-medications with simethicone (Lund et al. 1992;
Sisler and Tilcock 1995). Simethicone is a well-known
emulsifying agent that has been used previously in upper
gastrointestinal radiologic examinations to break down
large gas pockets by changing their surface tension. It is
also known to improve ultrasonographic visualization
of the pancreas and the retroperitoneum in association
with patient rotation (Abu-Yousef and El-Zein 2000;
Herrerıas-Gutierrez and Garcıa-Montes 1994;
P€aiv€ansalo and Suramo 1986; Varas and Lopez 1991).
However, the extensive use of pre-medication for all pa-
tients who have to undergo abdominal ultrasound is not
cost-effective and can subject some patients who do not
need pre-medication to adverse events related to these
pre-medications (Worlicek et al. 1989). The aim of this
study was to identify anthropometric parameters that
are able to predict a good response to simethicone oral
Factors predicting improved abdominal US after oral simethicone d M. MARSICO et al. 2533administration in terms of improving the ultrasono-
graphic visualization of pancreas, and other abdominal
structures. We have also compared prospectively two
different doses of oral simethicone to identify the best
dose in terms of cost/benefit ratio to use as pre-
medication for abdominal ultrasound.METHODS
One hundred twenty-seven consecutive patients
.20 and ,90 y old, who came to our outpatient clinic
to undergo abdominal ultrasound, were recruited. The
study was approved by the relevant local ethics commit-
tee, and Declaration of Helsinki protocols were fol-
lowed. Written informed consent was obtained from
all patients. Each patient was examined with basal
abdominal ultrasound. To quantify the visibility of the
structures, we chose landmarks of interest (LOIs:
pancreas head, body and tail; left hepatic lobe; caudate
lobe; right and left kidney; abdominal aorta; splenic
vein and spleen) that were used to calculate a LOI
score. The latter has been evaluated by the sum of the
visualized LOIs (0 5 LOI not visible or 1 5 LOI
visible). The maximum LOI score was defined as 10
points. After the basal ultrasound examination, the
following anthropometric parameters of patients were
collected: weight, height, waist circumference, abdom-
inal wall thickness. Patients were undressed for these
measurements. For each patient we used the same med-
ical instrumentations (meter and scales) previously cali-
brated and provided by our hospital. Weight and height
of patients were used to calculate the body mass index
(BMI). Patients were divided in two groups: group A
(34 patients) for patients with a complete abdominal ul-
trasonographic visualization (LOI score 5 10) and
group B (93 patients) with an incomplete abdominal ul-
trasonographic visualization (LOI score , 10). We
excluded from the study patients who had eaten or
smoked before the examination, who had not consumed
the prescribed amount of water before the examination,
who were unable to rotate three full turns on the exam-
ination bed and who could not stand upright if neces-
sary. The 93 patients from group B were randomly
divided into three subgroups. Patients in the first sub-
group drank 15 mL of a simethicone solution 1 h before
the US examination. Patients in the second subgroup
drank a complete therapeutic dose of simethicone
(15 mL 3 2/d) for 3 consecutive d before the examina-
tion. Patients in the third subgroup drank 15 mL of pla-
cebo solution 1 h before the examination. The placebo
solution was a mixture of water, sucrose, thickener and
lemon taste and was prepared to resemble, in taste and
texture, the simethicone solution. The study was per-
formed double blind; the simethicone or placebo solu-tion was delivered by the nurse. The examination was
performed by two expert ultrasonographers with the
same echograph, a ProSound Alfa7 (Hitachi-Aloka, To-
kyo, Japan) with a 3.75- to 7.5-MHz UST 91-30 Multi-
frequency Convex Abdominal HST (Hemispheric
Sound Technology) probe. The sonographers optimized
the image for each patient by changing such parameters
as the frequency of transmission, gain, time gain
compensation and dynamic range during the scan to
effectively select patients with poor visualization for
the study. All examinations were performed at the
fundamental frequency; tissue harmonic imaging
(THI) was never used. The mechanical index was
,1.9 as prescribed by U.S. Food and Drug Administra-
tion guidelines for ultrasound scanners. During the ex-
amination, each patient was rotated 180 to the right
and to the left three times, and only those for whom
visualization was incomplete were re-examined in the
upright position. The purpose of asking patients to
rotate is to induce a gas bowel displacement to improve
and maximize the visualization in agreement with what
is reported in the literature (Abu-Yousef and El-Zein
2000; Herrerıas-Gutierrez and Garcıa-Montes 1994;
P€aiv€ansalo and Suramo 1986; Varas and Lopez 1991).
The US examination lasted between 20 and 30 min.
Abdominal wall thickness was estimated when
performing the ultrasound measurement of the
subcutaneous adipose tissue at the level of the xiphoid
process. Data base construction and data analysis
were performed using Office Excel 2007, XLSTAT
2016 (Addinsoft) and SPSS for Windows (IBM,
Armonk, NY, USA). We examined the data with the
use of appropriate parametric and non-parametric statis-
tical tests (two-tailed Student t-test and Fischer’s c2
test, with p , 0.05 indicating significance); the likeli-
hood ratio and relative risk were calculated. A Lilliefors
(Kolmogorov–Smirnov) test for normality had been
performed earlier. With the degree of visualization of
the abdomen (complete group A or incomplete group
B) as a benchmark, sensitivity and specificity were
calculated for two definitions of waist circumference:
(i) greater than the cutoff value obtained and (ii) less
than the cutoff value. Sensitivity was calculated as the
number of patients with incomplete ultrasound visuali-
zation and waist circumference greater than the cutoff
value. Specificity was calculated as the number of pa-
tients with complete ultrasound visualization and waist
circumference less than the cutoff value. Receiver oper-
ating characteristic (ROC) curves was plotted, and the
areas under the ROC curves (AUCs) were calculated
along with their 95% confidence intervals (CIs). The
95% CIs were used to compare diagnostic capabilities.
The cutoff was calculated with ROC curve and ASC
analysis (Hanley and McNeil 1982).
Table 1. Main features of the groups
Anthropometric parameters
of patients
Group A
(n 5 34)
Group B
p Value (group
A/group B)Subgroup 1 (n 5 39) Subgroup 2 (n 5 38) Subgroup 3 (n 5 16)
Age, y 52.9 6 16.7 55.6 6 18.1 57.2 6 17.9 56.4 6 14.9 .0.05
Body mass index, kg/m2 23.23 6 2.89 26.04 6 4.09 26.74 6 4.49 25.75 6 3.82 .0.05
Waist circumference, cm 84 6 9.8 93.2 6 13.4 97.1 6 11.6 87.8 6 12.5 .0.05
Abdominal wall thickness, cm 2.03 6 0.61 2.50 6 1.04 2.66 6 1.09 2.36 6 0.74 .0.05
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One hundred twenty-seven consecutive patients (68
men, 59 women; 59, age: 56.46 16.7 y [mean6 standard
deviation]; BMI: 26.27 6 4.24 kg/m2; waist circumfer-
ence: 93.9 6 12.7 cm; abdominal wall thickness:
2.54 6 0.99 cm) who had undergone upper abdominal
US examination were enrolled in this study (Table 1).
There were 34 patients in group A (complete visualiza-
tion of the abdomen) and 93 patients in group B (incom-
plete visualization of the abdomen) (Fig. 1a, b). In group
B, the mean global visibility at the basal ultrasound ex-
amination was 5.82 (LOI score). After randomization,
39 patients were included in subgroup 1, 38 patients in
subgroup 2 and 16 patients in subgroup 3. In subgroups
1 and 2 (n 5 77), the mean global visibility was 5.66 at
the basal (first) ultrasound examination (subgroup 1: 6,
subgroup 2: 5.27), whereas in subgroup 3, the mean
global visibility was 6.69. In group B (incomplete visual-
ization of the abdomen), at the basal ultrasound examina-
tion, the pancreas was not fully viewable in 91 cases
(97.8%). In particular, the head was not visualized in 44
cases (48.4%), the body in 69 cases (75.8%) and the tail
in 90 cases (98.9%). In subgroup 1, the pancreas was
not completely viewable in 38 cases (97.4%), and theFig. 1. (a) Pancreas and epigastric structures not viewable for
simethicone. The red arrow indicates the splenic vein. (b)head was not visualized in 15 cases (39.5%), the pancreas
body in 30 cases (78.9%) and the pancreas tail in 38 cases
(100%). In subgroup 2, the pancreas was not completely
viewable in 37 cases (97.4%), and the head was not visu-
alized in 25 cases (67.6%), the body in 30 cases (81.1%)
and the tail in 36 cases (67.3%). In subgroup 3, the
pancreas was not completely viewable in all patients
(100%), and the head was not visualized in 4 (25%),
the body in 9 (56.3%) and the tail in 16 (100%). In group
B (incomplete visualization of the abdomen), the left lobe
or the caudate lobe of the liver was not viewable in 26
cases (27.9%), the right kidney in 3 cases (3.2%), the
left kidney in only 1 case (1.1%), the abdominal aorta
in 30 cases (34.1% of cases) and the splenic vein in 26
cases (32.3%). In all cases, the spleen was correctly visu-
alized. Mean global visibility at the second ultrasound ex-
amination was 8.13 for subgroup 1, 7.76 for subgroup 2
and 7.07 for subgroup 3. The pancreas was not fully view-
able in 50 cases (53.8%). In subgroup 1, the pancreas was
not completely viewable in 20 cases (51.3%); in subgroup
2, in 18 cases (47.4%); and in subgroup 3, in 12 cases
(75%). At the second US examination, the left lobe of
the liver was not viewable in 2 cases (2.2%), the abdom-
inal aorta in 12 cases (12.9% of cases) and the splenic
vein in 10 cases (10.8%). The spleen, right kidney andinter-position of abdominal gas before administration of
Viewable pancreas after simethicone administration.
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Fig. 2. Global visibility at the first and second ultrasonographic (US) examinations. p Values are reported in the text.
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calculated with the LOI score improved significantly af-
ter administration of simethicone solution (p , 0.01) in
subgroups 1 and 2. There was no significant improvement
in global visibility in subgroup 3 (placebo) (p. 0.05). In
particular, visualization of the pancreas improved signif-
icantly in subgroups 1 and 2 (p , 0.01), but not in sub-
group 3 (p . 0.05). At the second examination, the LOI
score was significantly higher in subgroups 1 and 2
with respect to subgroup 3 (placebo) (p , 0.01). No sta-
tistical difference in global visualization (LOI score) was
observed between the two different dosages of simethi-
cone solution (subgroups 1 and 2). Global and pancreas
visualization increased respectively from 37.6% to
44.7% at US examination after the administration of si-
methicone. LOIs were completely visualized (score at
second US examination 5 9) in 36 patients (38.7%).
Therewas 41.6% improvement in global US visualization0
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Fig. 3. ROC curve. ROC 5 receiver operating characteristic;
AUC 5 area under the ROC curve.in subgroups 1 and 2 together. Complete visualization of
the pancreas at the second US examination was achieved
in 41 patients (45.1%). The main visibility characteristics
of the different subgroups are illustrated in Figure 2. In
group A, the mean global visibility at the basal ultrasound
examination was the highest possible in LOI score. There
were 34 patients in this group (11 males and 23 females)
(age: 53.1 6 15.8 y; BMI: 22.56 6 3.43 kg/m2; waist
circumference: 83.26 9.6 cm; abdominal wall thickness:
1.93 6 0.70). There were some statistically significant
differences between groups A and B with respect to
BMI, waist circumference and abdominal wall thickness.
In particular, patients from group B were found to have
higher BMIs (p , 0.01), greater waist circumference
(p , 0.01) and thicker abdominal walls (p , 0.01) in
comparison with group A. In the total study population,
the sensitivity for incomplete visualization of the
abdomen at a waist circumference cutoff value of
84 cm was 90% (95% CI: 0.807–0.940), and specificity
was 73.5% (95% CI: 0.566–0.855). The AUC for waist
circumference was 0.864 (95% CI: 0.801–0.927) (Fig. 3).DISCUSSION
Ultrasonography is an important method for study-
ing the upper abdomen; nevertheless, the presence of
gas in the stomach and gut is the main reason for poor
visualization of important structures. Ultrasonographic
artifacts during air inter-position prevent visualization
of the underlying structures, resulting in the use of other
expensive diagnostic imaging techniques. Visualization
of the pancreas, in particular, is the major limitation. To
increase the visibility of the upper abdominal region,
medications that avoid the inter-position of air present
in the gastrointestinal lumen can be used in ultrasonogra-
phy. Simethicone is a carminative agent that can emulsify
foam and air bubbles in the gastrointestinal tract by
decreasing their superficial tension and permitting their
2536 Ultrasound in Medicine and Biology Volume 42, Number 11, 2016coalescence. Simethicone is a mixture of polydimethylsi-
loxane and hydrated silica gel. It is not absorbed by the
gut into the bloodstream and is therefore, considered rela-
tively tolerable. The National Institutes of Health (NIH)
reports there are usually no side effects with oral simethi-
cone. Contraindications are allergy to the active sub-
stance and intestinal obstruction. Small intestine
bacterial overgrowth syndrome (SIBO) is one of the
most common causes of excessive abdominal gas. Ac-
cording to the literature, already SIBO is commonly asso-
ciated with many pathologic conditions such as advanced
chronic liver disease (Chesta and Defilippi 1993; Stotzer
et al. 1996), obesity (Madrid et al. 1997; Tosetti et al.
1996), irritable bowel syndrome (Pimentel et al. 2003;
Posserud et al. 2007) and probably hepatic steatosis
(Sabate et al. 2008; Wittmann et al. 2010). Moreover,
we know that patients with common structural disorders
(such as diverticula) or functional disorders (alteration
of microbiota) of the colon are predisposed to the
development of gut bacterial overgrowth and excessive
abdominal gas (Brecevic et al. 1994; Goldstein and
Katragadda 1978; Madrid et al. 2011). An association
between SIBO or colonic disorders and obesity has
been already reported (Di Stefano et al. 2005; Skar
et al. 1989; Vantrappen et al. 1977). So, we believe that
patients with larger waist circumferences and
overweight, based on the BMI, have excessive bowel
gas, probably because of SIBO or colonic structural and
functional disorders. However, it is certain that a larger
waist circumference is related to a deeper pancreas and
more abdominal and mesenteric fat, which can
negatively influence ultrasound visualization, but
simethicone probably cannot influence this condition.
According to the available literature, our trial has
indicated that pre-medication with simethicone can
improve the diagnostic capability of upper abdominal ul-
trasonography, especially for pancreas visualization,
excluding the use of other expensive examinations such
as CT and MRI (Foster et al. 1984; Hessel et al. 1982;
Kamin et al. 1980; Pasanen et al. 1992). In our study,
we compared the benefits of two different types of
administration of simethicone as pre-medication for ul-
trasound examination. We compared standard therapeutic
doses of simethicone for 3 consecutive days before the
examination with a single simethicone administration
1 h before the ultrasound examination. We found that
pre-treatment with oral simethicone solution can improve
the accuracy of US upper abdomen examination
(p , 0.01), with an increase of 41.6% in global US visi-
bility. The single dose results in better dosage in terms of
the cost/benefit ratio. In addition, we found that patients
with the worst ultrasound visualization caused by gastro-
intestinal gas (group B) have greater BMI, waist circum-
ference and abdominal wall thickness in comparison withgroup A (patients with complete visualization). In our
study, the best anthropometric parameter for identifying
patients with a poor visualization at abdominal ultra-
sound examination is waist circumference. Using a cutoff
of 84 cm, we can identify patients with poor visibility at
abdominal ultrasound examination (group B) with a
sensitivity of 90%. Therefore, we propose that a few sim-
ple anthropometric predictive factors could identify pa-
tients who should routinely receive simethicone before
abdominal ultrasound. We conclude that values higher
than normal for BMI, abdominal wall thickness and, in
particular, waist circumference are predictive of the pres-
ence of excessive intestinal gas, which results in worse
visualization of the upper abdomen at ultrasound exami-
nation. For this reason, we propose that it would be useful
to routinely prescribe simethicone before abdominal ul-
trasound to patients with high values of these anthropo-
metric parameters, particularly waist circumference
.84 cm. Finally, we suggest that a single dose of simethi-
cone administered 1 h before the ultrasound examination
is the best pre-medication in terms of the cost/benefit
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